Literature DB >> 8788290

Indirect parameters of pancreatic function in cystic fibrosis (CF) during a controlled double-blind trial of pancreatic supplementation.

S Regele1, J Henker, R Münch, Y Barbier, M Stern.   

Abstract

During two treatment periods (4 weeks each), serum immunoreactive trypsin (IRT), immunoreactive human lipase in stool (IRL), and chymotrypsin (CT) activity in stool were determined in 16 cystic fibrosis patients and compared with fecal fat excretion (72-h sampling). Fecal fat estimation revealed mild to severe steatorrhea in all 16 patients (X = 13.7 +/- 9.0 g/24 h) in at least one study period. Stool fat excretion was highest in underweight adolescents and adults. Comparison of IRT and IRL with stool fat values showed no significant statistical correlation. IRT values revealed an inverse exponential correlation with age, with a steep decline at the age of 5 years. CT levels were very high in 14 of our 16 patients during supplementation therapy, whereas 2 patients showed subnormal CT values. We conclude that since indirect parameters of pancreatic function do not correlate with stool fat excretion, stool fat remains the best indirect parameter for the assessment of pancreatic insufficiency in cystic fibrosis. Leaving pancreatic enzyme supplementation in cystic fibrosis patients on the basis of normal serum trypsin or fecal lipase values does not appear to be adequate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8788290     DOI: 10.1097/00005176-199601000-00011

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  3 in total

1.  Colonic wall thickness measured by ultrasound: striking differences in patients with cystic fibrosis versus healthy controls.

Authors:  H P Haber; N Benda; G Fitzke; A Lang; M Langenberg; J Riethmüller; M Stern
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Lipid, nitrogen, water and energy content of a single stool sample in healthy children and children with cystic fibrosis.

Authors:  Anita Maria Van den Neucker; Pierre-Philippe Forget; Bernard van Kreel
Journal:  Eur J Pediatr       Date:  2003-08-27       Impact factor: 3.183

3.  Pancreatic enzyme replacement therapy for people with cystic fibrosis.

Authors:  Usha Rani R Somaraju; Arturo Solis-Moya
Journal:  Cochrane Database Syst Rev       Date:  2020-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.